Form D · Biotechnology
Lytica Therapeutics, Inc.
Cambridge, MA · CIK 0002015049
Offering snapshot reported Apr 11, 2025 · SEC filing
- Reported sold
- $6M Indefinite offering
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 28, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 11, 2025 | Initial | $6,000,000 | No comparison | 17 | SEC filing |
| Aug 19, 2024 | Initial | $1,750,000 | No comparison | 9 | SEC filing |
| Mar 12, 2024 | Initial | $4,065,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-543463
Source: Form D, filed Apr 11, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jean Francois Ducrest | Director |
| James Latorre | Director |
| Daniel Macaya | Director |
| Rida Mourtada | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
840 Memorial Drive
Cambridge, MA, 02139
Cambridge, MA, 02139